LISINOPRIL
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS · HYPERTENSION ·+2
QUALLENT PHARMA
Drug class
Angiotensin Inhibiting Agents
The term "angiotensin inhibiting agents" is a broad umbrella descriptor rather than a single distinct regulatory drug class, primarily encompassing pharmacologic classes that suppress the renin-angiotensin-aldosterone system. Read more about Angiotensin Inhibiting Agents
476 drugs in this class 114 manufacturers
Drugs in Angiotensin Inhibiting Agents
LOSARTAN POTASSIUM
ANGIOTENSIN II RECEPTOR ANTAGONISTS (ARBS) · DIABETIC NEPHROPATHY ·+2
QUALLENT PHARMA
OLMESARTAN MEDOXOMIL
ANGIOTENSIN II RECEPTOR ANTAGONISTS (ARBS) · HYPERTENSION
QUALLENT PHARMA
CAPTOPRIL
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS · DIABETIC NEPHROPATHY ·+3
MYLAN INSTITUTI
AMLODIPINE BESYLATE-BENAZEPRIL (amlodipine besylate/benazepril HCl)
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS · HYPERTENSION
PD-RX PHARM
BENAZEPRIL HCL
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS · HYPERTENSION
PD-RX PHARM
CAPTOPRIL
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS · DIABETIC NEPHROPATHY ·+3
PD-RX PHARM
ENALAPRIL MALEATE
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS · HYPERTENSION ·+2
PD-RX PHARM
LISINOPRIL
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS · HYPERTENSION ·+2
PD-RX PHARM
Filter & compare in the drug finder →
Opens the drug finder with Angiotensin Inhibiting Agents preselected. Add indication or manufacturer filters there.
The term "angiotensin inhibiting agents" is a broad umbrella descriptor rather than a single distinct regulatory drug class, primarily encompassing pharmacologic classes that suppress the renin-angiotensin-aldosterone system.
Most notably, this grouping includes angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), alongside direct renin inhibitors.
These agents work by preventing the formation of angiotensin II or selectively blocking its binding to vascular receptors, which promotes vasodilation, reduces systemic vascular resistance, and decreases aldosterone secretion.
Clinically, these medications serve as foundational therapies across major cardiovascular and renal conditions, including hypertension, heart failure with reduced ejection fraction, post-myocardial infarction ventricular dysfunction, and chronic kidney disease, particularly diabetic nephropathy.
-
fda.gov
The term "angiotensin inhibiting agents" is a broad umbrella descriptor rather than a single distinct regulatory drug class, primarily encompassing pharmacologic classes that suppress the renin-angiotensin-aldosterone system
-
nih.gov
The term "angiotensin inhibiting agents" is a broad umbrella descriptor rather than a single distinct regulatory drug class, primarily encompassing pharmacologic classes that suppress the renin-angiotensin-aldosterone system
-
nih.gov
Most notably, this grouping includes angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), alongside direct renin inhibitors
-
mayoclinic.org
Most notably, this grouping includes angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), alongside direct renin inhibitors These agents work by preventing the formation of angiotensin II or selectively blocking its binding to vascular receptors, which promotes vasodilation, reduces systemic vascular resistance, and decreases aldosterone secretion Clinically, these medications serve as foundational therapies across major cardiovascular and renal conditions,...
-
nih.gov
Clinically, these medications serve as foundational therapies across major cardiovascular and renal conditions, including hypertension, heart failure with reduced ejection fraction, post-myocardial infarction ventricular dysfunction, and chronic kidney disease, particularly diabetic nephropathy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.